Format

Send to

Choose Destination
See comment in PubMed Commons below
Mol Interv. 2005 Jun;5(3):163-71.

The cardiotoxicology of anthracycline chemotherapeutics: translating molecular mechanism into preventative medicine.

Author information

1
Whitaker Cardiovascular Institute and Center for Molecular Stress Response, Boston University Medical Center, 650 Albany Street, Boston, MA 02118, USA.

Abstract

Anthracyclines remain a mainstay of chemotherapy in spite of their well-recognized cardiotoxicity. Recent experience with trastuzumab (Herceptin) and anthracycline therapy has prompted a detailed analysis of the function of erbB2 in the heart. These studies demonstrate a cardioprotective effect of neuregulin, the endogenous ligand for the erbB4/erbB2 heterodimeric receptor complex. Although the mechanisms of cytoprotection remain incompletely understood, these studies have triggered the question of whether physiological manipulation of cardioprotective pathways that involve erbB can be used to improve outcome in patients treated with anthracyclines. The local activation of cardioprotection by cardiovascular exercise may be such a manipulation and warrants further investigation.

PMID:
15994456
DOI:
10.1124/mi.5.3.6
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Support Center